Fanny Le Du
Overview
Explore the profile of Fanny Le Du including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
523
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Le Du F, Moati E, Vaflard P, Bailleux C, Pierga J, Dieras V
Bull Cancer
. 2024 Nov;
112(1):82-99.
PMID: 39510910
Triple negative breast cancer (TNBC) is defined by the absence of expression of estrogen and progesterone receptors, as well as the absence of overexpression of HER2. Accounting for 10 to...
2.
Frenel J, Zeghondy J, Guerin-Charbonnel C, Mailliez A, Volant E, Poumeaud F, et al.
JAMA Netw Open
. 2024 Apr;
7(4):e244435.
PMID: 38568692
Importance: Little is known regarding the outcomes associated with tucatinib combined with trastuzumab and capecitabine (TTC) after trastuzumab-deruxtecan exposure among patients with ERBB2 (previously HER2)-positive metastatic breast cancer (MBC). Objective:...
3.
Corne J, Quillien V, Godey F, Cherel M, Cochet A, Le Du F, et al.
Mol Oncol
. 2024 Jan;
18(11):2714-2729.
PMID: 38287892
Erb-b2 receptor tyrosine kinase 2 (ERBB2)-activating mutations are therapeutically actionable alterations found in various cancers, including metastatic breast cancer (MBC). We developed multiplex digital PCR assays to detect and quantify...
4.
Le Du F, Carton M, Bachelot T, Saghatchian M, Pistilli B, Brain E, et al.
Oncologist
. 2023 Aug;
28(10):e867-e876.
PMID: 37589218
Background: Although adjuvant cancer treatments increase cure rates, they may induce clonal selection and tumor resistance. Information still lacks as whether (neo)adjuvant anti-HER2 treatments impact the patterns of recurrence and...
5.
Deleuze A, Massard C, Le Du F, You B, Lefeuvre-Plesse C, Bolze P, et al.
Expert Rev Anticancer Ther
. 2023 May;
23(7):699-708.
PMID: 37198729
Introduction: Gestational trophoblastic neoplasia (GTN) is a group of rare tumors characterized by abnormal trophoblastic proliferation following pregnancy including invasive moles, choriocarcinomas, and intermediate trophoblastic tumors (ITT). Although the treatment...
6.
Corne J, Quillien V, Callens C, Portois P, Bidard F, Jeannot E, et al.
Clin Chim Acta
. 2023 Apr;
545:117366.
PMID: 37105452
Background: Early detection of ESR1 mutations is a key element for better personalization of the management of patients with HR+/HER2- Metastatic Breast Cancer (MBC). Analysis of circulating tumor DNA from...
7.
Bellier C, Gladieff L, Le Du F, Berton D, Bonnard C, Suau D, et al.
Drugs Real World Outcomes
. 2023 Jan;
10(2):207-213.
PMID: 36630055
Background: Olaparib, a poly(ADP-ribose) polymerase inhibitor, was approved by the European Commission in June 2019, following the results of the SOLO-1/GOG 3004 trial as maintenance monotherapy in adult patients with...
8.
Refining Therapy in Patients with HER2-Positive Breast Cancer with Central Nervous System Metastasis
Batista M, Eiriz I, Fitzpatrick A, Le Du F, Braga S, Costa D
Breast Care (Basel)
. 2023 Jan;
17(6):524-532.
PMID: 36590149
Background: Brain metastasis (BM) is a major clinical problem in metastatic breast cancer (MBC), occurring in 50% of patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Historically...
9.
Francis P, Fleming G, Lang I, Ciruelos E, Bonnefoi H, Bellet M, et al.
J Clin Oncol
. 2022 Dec;
41(7):1370-1375.
PMID: 36493334
JCO The Suppression of Ovarian Function Trial (SOFT; ClinicalTrials.gov identifier: NCT00066690) randomly assigned premenopausal women with hormone receptor-positive breast cancer to 5 years of adjuvant tamoxifen, tamoxifen plus ovarian function...
10.
Veron M, Chevret S, Grob J, Beylot-Barry M, Saiag P, Flechon A, et al.
Eur J Cancer
. 2022 Nov;
177:103-111.
PMID: 36335780
Background: Basal cell carcinoma (BCC) is the most common human malignancy. In most cases, BCC has slow progression and can be definitively cured by surgery or radiotherapy. However, in rare...